Pneumococcal pneumonia leads to 150,000 hospitalizations alone annually, and pneumococci cause over half of all cases of bacterial meningitis in the U.S. As an essential part of the country’s immune system, pharmacies are well-positioned to help protect communities from those outcomes. In a Business Booster webinar tomorrow, Aug. 4 at 2 p.m. ET, Pfizer will explore strategies to help protect eligible adult patients against pneumococcal disease caused by medically important serotypes.
Topics include the burden of pneumococcal disease in adults, the importance of direct protection with Prevnar 20, Prevnar 13 efficacy and effectiveness (including findings from the CAPiTA trial and real-world data), current ACIP adult pneumococcal vaccination recommendations and clinical scenarios, and the critical role health care providers play in improving adult vaccination rates.
Learn more about our other webinar offerings, including our Business Booster webinar archive, here.
